AAAAAA
Results: 1-25/26
Authors:
Cozzolino, M
Dusso, CS
Slatopolsky, E
Citation: M. Cozzolino et al., Role of calcium-phosphate product and bone-associated proteins on vascularcalcification in renal failure, J AM S NEPH, 12(11), 2001, pp. 2511-2516
Authors:
Slatopolsky, E
Brown, A
Dusso, A
Citation: E. Slatopolsky et al., Role of phosphorus in the pathogenesis of secondary hyperparathyroidism, AM J KIDNEY, 37(1), 2001, pp. S54-S57
Authors:
Sherrard, DJ
Martin, KJ
Slatopolsky, E
Citation: Dj. Sherrard et al., A roundtable discussion - Should vitamin D analogs be the therapy of preference for ESRD patients with secondary hyperparathyroidism?, DIALYSIS T, 30(4), 2001, pp. 190
Authors:
Cozzolino, M
Lu, Y
Finch, J
Slatopolsky, E
Dusso, AS
Citation: M. Cozzolino et al., p21(WAF1) and TGF-alpha mediate parathyroid growth arrest by vitamin D andhigh calcium, KIDNEY INT, 60(6), 2001, pp. 2109-2117
Authors:
Slatopolsky, E
Citation: E. Slatopolsky, 7-84 PTH or aluminum antagonism in the resistance of uremic bone to the remodeling effect of endogenous PTH? Reply, KIDNEY INT, 59(6), 2001, pp. 2376-2376
Authors:
Dusso, AS
Pavlopoulos, T
Naumovich, L
Lu, Y
Finch, J
Brown, AJ
Morrissey, J
Slatopolsky, E
Citation: As. Dusso et al., P21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth, KIDNEY INT, 59(3), 2001, pp. 855-865
Authors:
Huang, ZM
Cheng, SL
Slatopolsky, E
Citation: Zm. Huang et al., Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation, J BIOL CHEM, 276(24), 2001, pp. 21351-21358
Authors:
Brown, AJ
Finch, J
Takahashi, F
Slatopolsky, E
Citation: Aj. Brown et al., Calcemic activity of 19-Nor-1,25(OH)(2)D-2 decreases with duration of treatment, J AM S NEPH, 11(11), 2000, pp. 2088-2094
Authors:
Holliday, LS
Gluck, SL
Slatopolsky, E
Brown, AJ
Citation: Ls. Holliday et al., 1,25-dihydroxy-19-nor-vitamin D-2, a vitamin D analog with reduced bone resorbing activity in vitro, J AM S NEPH, 11(10), 2000, pp. 1857-1864
Authors:
Chertow, GM
Burke, SK
Dillon, MA
Slatopolsky, E
Citation: Gm. Chertow et al., Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients (vol 14, pg 2907, 1999), NEPH DIAL T, 15(4), 2000, pp. 559-559
Authors:
Chertow, GM
Plone, M
Dillon, MA
Burke, SK
Slatopolsky, E
Citation: Gm. Chertow et al., Hyperparathyroidism and dialysis vintage, CLIN NEPHR, 54(4), 2000, pp. 295-300
Authors:
Delmez, JA
Kelber, J
Norwood, KY
Giles, KS
Slatopolsky, E
Citation: Ja. Delmez et al., A controlled trial of the early treatment of secondary hyperparathyroidismwith calcitriol in hemodialysis patients, CLIN NEPHR, 54(4), 2000, pp. 301-308
Authors:
Bleyer, AJ
Burke, S
Slatopolsky, E
Citation: Aj. Bleyer et al., Untitled - In reply, AM J KIDNEY, 35(6), 2000, pp. 1249-1250
Authors:
Slatopolsky, E
Finch, J
Clay, P
Martin, D
Sicard, G
Singer, G
Gao, P
Cantor, T
Dusso, A
Citation: E. Slatopolsky et al., A novel mechanism for skeletal resistance in uremia, KIDNEY INT, 58(2), 2000, pp. 753-761
Authors:
Chertow, GM
Burke, SK
Dillon, MA
Slatopolsky, E
Citation: Gm. Chertow et al., Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients, NEPH DIAL T, 14(12), 1999, pp. 2907-2914
Authors:
Brown, AJ
Ritter, C
Slatopolsky, E
Muralidharan, KR
Okamura, WH
Reddy, GS
Citation: Aj. Brown et al., 1 alpha,25-dihydroxy-3-epi-vitamin D-3, a natural metabolite of 1 alpha,25-dihydroxyvitamin D-3, is a potent suppressor of parathyroid hormone secretion, J CELL BIOC, 73(1), 1999, pp. 106-113
Authors:
Brown, AJ
Slatopolsky, E
Citation: Aj. Brown et E. Slatopolsky, Vitamin D analogs: Perspectives for treatment, MIN ELECT M, 25(4-6), 1999, pp. 337-341
Authors:
Brown, AJ
Dusso, A
Slatopolsky, E
Citation: Aj. Brown et al., Vitamin D, AM J P-REN, 46(2), 1999, pp. F157-F175
Authors:
Chertow, GM
Dillon, M
Burke, SK
Steg, M
Bleyer, AJ
Garrett, BN
Domoto, DT
Wilkes, BM
Wombolt, DG
Slatopolsky, E
Citation: Gm. Chertow et al., A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients, CLIN NEPHR, 51(1), 1999, pp. 18-26
Authors:
Bleyer, AJ
Burke, SK
Dillon, M
Garrett, B
Kant, KS
Lynch, D
Rahman, SN
Schoenfeld, P
Teitelbaum, I
Zeig, S
Slatopolsky, E
Citation: Aj. Bleyer et al., A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients, AM J KIDNEY, 33(4), 1999, pp. 694-701
Authors:
Gokal, R
Hutchison, AJ
Ritz, E
Slatopolsky, E
Citation: R. Gokal et al., Untitled - Introduction, KIDNEY INT, 56, 1999, pp. S1-S1
Authors:
Slatopolsky, E
Brown, A
Dusso, A
Citation: E. Slatopolsky et al., Pathogenesis of secondary hyperparathyroidism, KIDNEY INT, 56, 1999, pp. S14-S19
Authors:
Slatopolsky, E
Dusso, A
Brown, A
Citation: E. Slatopolsky et al., New analogs of vitamin D-3, KIDNEY INT, 56, 1999, pp. S46-S51
Authors:
Monier-Faugere, MC
Geng, ZP
Friedler, RM
Qi, QL
Kubodera, N
Slatopolsky, E
Malluche, HH
Citation: Mc. Monier-faugere et al., 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducinglow bone turnover in dogs with renal failure, KIDNEY INT, 55(3), 1999, pp. 821-832
Authors:
Huang, ZM
Ritter, C
Brown, A
Finch, J
Abu-Amer, Y
Ross, P
Slatopolsky, E
Citation: Zm. Huang et al., Cloning and localization of Rab3 isoforms in bovine, rat, and human parathyroid glands, BIOC BIOP R, 255(3), 1999, pp. 645-651